Recent Updates
Recently added Catalysts

SBRT

Phase 3

Nonsmall Cell Lung Cancer Stage | Unknown | Oncology |Accuray Incorporated|Last Updated: Oct 1, 2026

Development status

Highest phase Phase 3 run by Institute of Cancer Research, United Kingdom (NCT05613023)
Phase scored for ARAYPhase 1
Registered trials 27 across 16 sponsors since Jan 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment35

FDA Designations

No designations recorded

Clinical trial landscape

SBRT · 1 trial · 1 indication

Phase 1 1
NCT07852247SBRT for Ultra-Central NonSmall Cell Lung CancerNonsmall Cell Lung Cancer Stage
NOT YET_RECRUITING35 Analytics
PHASE1NOT YET_RECRUITING
SBRT for Ultra-Central NonSmall Cell Lung Cancer
Nonsmall Cell Lung Cancer Stage
NCT0785224735
Unlock trial analytics

Study Endpoints

Primary Endpoints

Cumulative incidence of grade 3 or higher toxicity following SBRT with CyberKnife regimen with real-time motion tracking for ultra-central NSCLC.
Patients will be assessed for toxicity throughout treatment with radiation therapy (RT). Following RT, all participants will be evaluated through 12 months for the primary safety endpoint and will continue protocol safety follow-up through 5 years.

The primary safety endpoint is the cumulative incidence of acute or late grade ≥3 AEs occurring within 12 months and assessed as possibly, probably, or definitely related to protocol treatment. AEs will be graded using the NCI CTCAE version 6.0. Prespecified thoracic AEs include dyspnea, cough, pneumonitis, lung infection, atelectasis, bronchial stenosis or obstruction, bronchopulmonary hemorrhage or hemoptysis, fistula, dysphagia or esophagitis, pleural or pericardial effusion, and chest pain.

Secondary Endpoints

Local control (LC)
Until Trial Completed (up to 5 years)
Regional nodal progression
Until Trial Completed (up to 5 years)
Distant metastasis-free survival (DMFS)
Until trial completed (up to 5 years)
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cyberknife with Synchrony Motion TrackingEXPERIMENTAL -

Interventions

NameTypeDescription
SBRTRADIATION50 Grays (Gy) delivered in 5 fractions, delivered using Cyberknife with Synchrony motion tracking, every other day over 2 weeks.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Patients aged 18 or older. 2. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 3. Patients with confirmed tumor location using advanced imaging to ensure accurate classification of ultra-central NSCLC. 4. Ability to undergo bronchoscopy an...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 1, 2026NCT07852247NEW_TRIAL: changed
LOWOct 1, 2026NCT07852247NEW_TRIAL: changed

Explore more on BiopharmaWatch

Accuray Incorporated (ARAY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with SCompanies A to ZEvery biotech and pharma company we track